NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma
Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Joseph P. McGuirk(University of Kansas Medical Center), Catherine Diefenbach(NYU Langone Health), Saurabh Dahiya(Stanford University), Sohail S. Chaudhry(Nektar Therapeutics (United States)), Cristina Castilla‐Llorente(Institut Gustave Roussy), James Essell(Oncology Hematology Care), John F. DiPersio(Washington University in St. Louis), Mary Tagliaferri(Nektar Therapeutics (United States)), David B. Miklos(Stanford University), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Christie Fanton(Nektar Therapeutics (United States)), Cameron J. Turtle(The University of Sydney), Heng Xu(Nektar Therapeutics (United States)), A Mario Q. Marcondes(Nektar Therapeutics (United States)), Yi Liu(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k